More on Alkermes' (ALKS) FQ4 : Revenues from five key commercial products rise +26% Y/Y and free...

|About: Alkermes plc (ALKS)|By:, SA News Editor

More on Alkermes' (ALKS) FQ4 : Revenues from five key commercial products rise +26% Y/Y and free cash flow jumps to $48M from $8.4M. For the full year (the first full year that reflects the Elan Drug merger) revenues and (non-GAAP) net income rise 48% and 285% to $575.5M and $1.31/share respectively. AMPYRA/FAMPYRA revenues were $65M for the full year vs. $24.6M for FY12 and VIVITROL revenues rose 41% Y/Y to $58.1M. Operating expenses ex a one-time restructuring charge were essentially flat. (PR)